{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T19:18:27Z","timestamp":1761765507951},"reference-count":51,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2012,3,21]],"date-time":"2012-03-21T00:00:00Z","timestamp":1332288000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J of Urology"],"published-print":{"date-parts":[[2012,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Androgen deprivation therapy is commonly used in men with advanced prostate cancer; however, it is associated with many short\u2010 and long\u2010term side\u2010effects. Intermittent androgen deprivation therapy was first suggested as an alternative regimen in the early 1990s and is now part of treatment guidelines as a result of its ability to reduce adverse events associated with continuous androgen deprivation therapy without decreasing its efficacy. Although many publications evaluated intermittent androgen deprivation therapy's efficacy, the safety and tolerability information of this regimen is relatively limited. The goal of this literature review was to analyze clinical trials that have reported safety and tolerability data in prostate cancer patients treated with intermittent androgen deprivation therapy, as well as assessing quality of life outcomes. A literature search was carried out using biomedical and pharmaceutical databases for published information comparing intermittent androgen deprivation therapy with continuous androgen deprivation therapy. A total of 13 randomized and non\u2010randomized studies were selected and reviewed based on their relevance to the safety, tolerability and quality of life of intermittent androgen deprivation therapy. Benefits for intermittent androgen deprivation therapy were observed for the short\u2010term side\u2010effects (hot flushes and sexual functions) mainly during the off\u2010treatment phase, whereas the data for the long\u2010term side\u2010effects were not as conclusive. Quality of life evaluations are more in support of intermittent androgen deprivation therapy. Although there are some safety, tolerability and quality of life benefits associated with intermittent androgen deprivation therapy, the overall evidence is still limited.<\/jats:p>","DOI":"10.1111\/j.1442-2042.2012.03001.x","type":"journal-article","created":{"date-parts":[[2012,3,23]],"date-time":"2012-03-23T00:16:24Z","timestamp":1332461784000},"page":"614-625","source":"Crossref","is-referenced-by-count":17,"title":["Safety and tolerability of intermittent androgen deprivation therapy: A literature review"],"prefix":"10.1111","volume":"19","author":[{"given":"Damian","family":"Gruca","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Bacher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulf","family":"Tunn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,3,21]]},"reference":[{"key":"e_1_2_8_2_2","doi-asserted-by":"publisher","DOI":"10.3322\/canjclin.22.4.232"},{"key":"e_1_2_8_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(02)01560-1"},{"key":"e_1_2_8_4_2","doi-asserted-by":"publisher","DOI":"10.1159\/000075960"},{"key":"e_1_2_8_5_2","first-page":"52","article-title":"Effective testosterone suppression for prostate cancer: is there a best castration therapy?","volume":"11","author":"Gomella LG","year":"2009","journal-title":"Rev. Urol."},{"key":"e_1_2_8_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2009.08924.x"},{"key":"e_1_2_8_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2009.11.009"},{"key":"e_1_2_8_8_2","unstructured":"HeidenreichA BollaM JoniauSet\u2003al.Guidelines on prostate cancer. [Cited 19 Apr 2011.] Available from URL:http:\/\/www.uroweb.org\/gls\/pdf\/Prostate%20Cancer%202010%20June%2017th.pdf"},{"key":"e_1_2_8_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2006.03.013"},{"key":"e_1_2_8_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2004.07.019"},{"key":"e_1_2_8_11_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.06.2497"},{"key":"e_1_2_8_12_2","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2010.0014"},{"key":"e_1_2_8_13_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1020840311573"},{"key":"e_1_2_8_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23440"},{"key":"e_1_2_8_15_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.8-5-474"},{"key":"e_1_2_8_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1743-6109.2010.01902.x"},{"key":"e_1_2_8_17_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.17.3750"},{"key":"e_1_2_8_18_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01542054"},{"volume-title":"Campbell\u2010Walsh Urology","year":"2011","author":"Wein A","key":"e_1_2_8_19_2"},{"key":"e_1_2_8_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2005.03.018"},{"key":"e_1_2_8_21_2","first-page":"263","article-title":"Incidence and management of hot flushes in prostate cancer","volume":"1","author":"Spetz AC","year":"2003","journal-title":"J. Support. Oncol."},{"key":"e_1_2_8_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(00)00084-8"},{"key":"e_1_2_8_23_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1464-410X.1997.00234.x"},{"key":"e_1_2_8_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(99)00301-5"},{"key":"e_1_2_8_25_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2005-2507"},{"key":"e_1_2_8_26_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.20.0923"},{"key":"e_1_2_8_27_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19930501)71:9<2782::AID-CNCR2820710916>3.0.CO;2-Z"},{"key":"e_1_2_8_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(99)80092-2"},{"key":"e_1_2_8_29_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2007.06596.x"},{"key":"e_1_2_8_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1569-9056(03)80094-5"},{"key":"e_1_2_8_31_2","unstructured":"Sanchez\u2010SalasR PrapotnichD SecinFet\u2003al.Intermittent androgen deprivation as secondary therapy for biochemical recurrence of localized prostate cancer(Abstract). American Urological Association May 14\u201019; Washington DC USA.2011."},{"key":"e_1_2_8_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2009.02.016"},{"key":"e_1_2_8_33_2","doi-asserted-by":"publisher","DOI":"10.3816\/CGC.2002.n.018"},{"key":"e_1_2_8_34_2","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/S0022-5347(18)38683-X","article-title":"Intermittent is as effective as continuous androgen deprivation in patients with PSA\u2010relapse after radical prostatectomy","volume":"171","author":"Tunn UW","year":"2004","journal-title":"J. Urol."},{"issue":"7","key":"e_1_2_8_35_2","article-title":"A phase III randomized trial comparing intermittent versus continuous androgen suppression for patients with PSA progression after radical therapy: NCIC CTG PR.7\/SWOG JPR.7\/CTSU JPR.7\/UK Intercontinental Trial CRUKE\/01\/013","volume":"29","author":"Klotz L","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"e_1_2_8_36_2","doi-asserted-by":"crossref","first-page":"5015","DOI":"10.1200\/jco.2007.25.18_suppl.5015","article-title":"Randomised prospective study of intermittent versus continuous androgen suppression in advanced prostate cancer","volume":"25","author":"Miller K","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"e_1_2_8_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1569-9056(08)60534-5"},{"issue":"4","key":"e_1_2_8_38_2","first-page":"397","article-title":"Intermittent androgen suppression for the treatment of advanced prostate cancer","volume":"169","author":"Schasfoort E","year":"2003","journal-title":"J. Urol."},{"key":"e_1_2_8_39_2","unstructured":"VerhagenPCMS WissenburgLD WildhagenMF(eds)Quality of life effects of intermittent and continuous hormonal therapy by cyproterone acetate (CPA) for metastatic prostate cancer(Abstract 541). 23rd Annual Congress of the European Association of Urology March 26\u201329; Milan Italy.2008."},{"key":"e_1_2_8_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1569-9056(09)60052-X"},{"key":"e_1_2_8_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(03)00961-1"},{"key":"e_1_2_8_42_2","doi-asserted-by":"publisher","DOI":"10.1159\/000020353"},{"key":"e_1_2_8_43_2","doi-asserted-by":"publisher","DOI":"10.3816\/CGC.2008.n.008"},{"key":"e_1_2_8_44_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2006.01.029"},{"key":"e_1_2_8_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1569-9056(08)60536-9"},{"key":"e_1_2_8_46_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2005.05676.x"},{"key":"e_1_2_8_47_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djp404"},{"key":"e_1_2_8_48_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.109.192695"},{"key":"e_1_2_8_49_2","doi-asserted-by":"crossref","unstructured":"PunnenS CooperbergM SadetskyN FuldeoreM CarrollP.editors. Causes of mortality following treatment for prostate cancer: what is the impact of androgen deprivation(Abstract 721). American Urological Association Annual meeting May 14\u201319; Washington DC USA.2011.","DOI":"10.1016\/j.juro.2011.02.1689"},{"key":"e_1_2_8_50_2","unstructured":"TunnU KlotzL. Personal communication at the 12th Australasian Prostate Cancer Conference Melbourne2011."},{"key":"e_1_2_8_51_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2007.08.012"},{"key":"e_1_2_8_52_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2009.07.049"}],"container-title":["International Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1442-2042.2012.03001.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1442-2042.2012.03001.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T04:55:27Z","timestamp":1697345727000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1442-2042.2012.03001.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3,21]]},"references-count":51,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2012,7]]}},"alternative-id":["10.1111\/j.1442-2042.2012.03001.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1442-2042.2012.03001.x","archive":["Portico"],"relation":{},"ISSN":["0919-8172","1442-2042"],"issn-type":[{"type":"print","value":"0919-8172"},{"type":"electronic","value":"1442-2042"}],"subject":[],"published":{"date-parts":[[2012,3,21]]}}}